0001209191-18-019258.txt : 20180313 0001209191-18-019258.hdr.sgml : 20180313 20180313165454 ACCESSION NUMBER: 0001209191-18-019258 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180309 FILED AS OF DATE: 20180313 DATE AS OF CHANGE: 20180313 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MacKenzie Lloyd CENTRAL INDEX KEY: 0001600164 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 18687144 MAIL ADDRESS: STREET 1: C/O AQUINOX PHARMACEUTICALS, INC. STREET 2: 450 - 887 GREAT NORTHERN WAY CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: SUITE 450 CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 BUSINESS PHONE: 604-629-9223 MAIL ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: SUITE 450 CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-09 0 0001404644 AQUINOX PHARMACEUTICALS, INC AQXP 0001600164 MacKenzie Lloyd C/O AQUINOX PHARMACEUTICALS, INC. 450 - 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Operating Officer Stock Option (Right to Buy) 16.55 2018-03-09 4 A 0 75000 0.00 A 2028-03-08 Common Stock 75000 75000 D The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of March 9, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date. /s/ Lloyd Mackenzie 2018-03-13